(HealthDay News) — For patients with end-stage renal disease (ESRD), receipt of hemodialysis (HD) is associated with increased mortality after radiofrequency ablation (RFA) for hepatocellular carcinoma, according to a study published online in the Journal of Gastroenterology and Hepatology.

Masaya Sato, from the University of Tokyo, and colleagues used a nationwide database to examine in-hospital mortality and hemorrhagic complications following RFA among patients on HD for ESRD. For each patient enrolled, up to 4 non-dialyzed patients were randomly selected. The authors compared in-hospital mortality and hemorrhagic complications between dialyzed and non-dialyzed patients (437 and 1345 patients, respectively) following RFA.

The researchers found that mortality was significantly lower in those aged ≤70 years vs older patients (P=.02). Dialyzed ESRD patients had significantly higher in-hospital mortality than non-dialyzed patients (1.1% vs 0.15%; odds ratio, 7.77; P<.001). There was a significant difference in hemorrhagic complications between dialyzed ESRD and non-dialyzed patients (3.4% and 0.87%, respectively; odds ratio, 4.75; P<.001).

Continue Reading

“In-hospital mortality following RFA was higher in dialyzed ESRD patients than in non-dialyzed patients,” the authors write. “The indications for RFA in dialysis-dependent patients should be considered carefully.”

Related Articles


  1. Sato M, Tateishi R, Yasunaga H, et al. Mortality and hemorrhagic complications associated with radiofrequency ablation for treatment of hepatocellular carcinoma in patients on hemodialysis for end-stage renal disease: a nationwide survey. J Gastroenterol Hepatol. 7 March 2017. doi: 10.1111/jgh.13780